Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Acquires $152,000.00 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CFO Alan Fuhrman bought 9,500 shares of the stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $152,000.00. Following the acquisition, the chief financial officer now owns 12,849 shares of the company’s stock, valued at approximately $205,584. This represents a 200.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Tyra Biosciences Stock Down 1.7 %

NASDAQ TYRA traded down $0.29 during mid-day trading on Friday, hitting $16.39. The stock had a trading volume of 523,453 shares, compared to its average volume of 186,846. The company has a 50 day simple moving average of $22.51 and a 200 day simple moving average of $19.87. The company has a market cap of $865.56 million, a price-to-earnings ratio of -9.70 and a beta of 1.01. Tyra Biosciences, Inc. has a 52-week low of $10.60 and a 52-week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. As a group, equities analysts anticipate that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TYRA has been the subject of a number of recent analyst reports. Wedbush restated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Friday, October 25th. Oppenheimer lifted their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. HC Wainwright upped their price objective on Tyra Biosciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Monday. Piper Sandler started coverage on Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. Finally, Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $31.40.

Institutional Trading of Tyra Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. boosted its stake in shares of Tyra Biosciences by 43.9% during the 1st quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares during the last quarter. BVF Inc. IL raised its position in shares of Tyra Biosciences by 70.1% in the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after buying an additional 1,921,599 shares during the last quarter. Perceptive Advisors LLC lifted its stake in shares of Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after buying an additional 338,208 shares during the period. Vanguard Group Inc. boosted its position in Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after acquiring an additional 140,833 shares during the last quarter. Finally, Kynam Capital Management LP grew its stake in Tyra Biosciences by 51.4% in the 1st quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after acquiring an additional 175,000 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.